Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells $523,093.75 in Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 110,125 shares of the stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $4.75, for a total value of $523,093.75. Following the sale, the insider owned 1,006,439 shares of the company’s stock, valued at $4,780,585.25. This represents a 9.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Sukumar Nagendran also recently made the following trade(s):

• On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.51, for a total value of $1,172,811.97.
• On Wednesday, September 10th, Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $3.23, for a total transaction of $646,000.00.

Taysha Gene Therapies Price Performance

TSHA stock opened at $4.49 on Thursday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. The company’s fifty day moving average price is $4.45 and its 200-day moving average price is $3.34. Taysha Gene Therapies, Inc. has a one year low of $1.05 and a one year high of $5.51. The company has a market capitalization of $1.23 billion, a PE ratio of -13.61 and a beta of 1.06.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. On average, equities analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors have recently bought and sold shares of TSHA. Jefferies Financial Group Inc. increased its position in Taysha Gene Therapies by 4,105.3% during the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after acquiring an additional 10,068,479 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in shares of Taysha Gene Therapies during the 2nd quarter worth about $11,178,000. Barclays PLC grew its holdings in Taysha Gene Therapies by 1,042.8% during the 3rd quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock valued at $16,834,000 after purchasing an additional 4,697,611 shares during the last quarter. MPM Bioimpact LLC purchased a new stake in Taysha Gene Therapies in the 2nd quarter worth about $6,823,000. Finally, Vestal Point Capital LP lifted its stake in Taysha Gene Therapies by 83.3% in the third quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock worth $17,985,000 after purchasing an additional 2,500,000 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TSHA has been the topic of several research reports. Citizens Jmp lifted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 5th. Wells Fargo & Company lifted their price objective on Taysha Gene Therapies from $7.50 to $8.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Taysha Gene Therapies in a report on Friday, October 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of Taysha Gene Therapies in a research report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.30.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.